Prostate cancer begins as an androgen-dependent tumor that undergoes clinical regression in response to pharmacological or surgical strategies that reduce testosterone concentration. Despite this ...

A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...

In a recent study published by Nature Communications, researchers uncovered a previously unknown method by which androgen-activated androgen receptors (ARs) increase fucosyltransferase 4 (FUT4) ...

The dinuclear platinum(II) complexes inhibit prostate cancer cell growth by binding to the androgen receptor (AR) and disrupting AR-mediated gene expression. This mechanism leads to apoptosis and ...

“Nothing Is as Great a Learning Experience as Getting a $15,000 Bill”: A Mixed-Methods Study of Young Adult Cancer Survivors' Experience With Insurance Coverage The following represents disclosure ...

A meta-analysis involving 21,260 patients with advanced or metastatic prostate cancer confirms increased risks of falls and fractures with the addition of androgen receptor signaling inhibitors to ...

Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

The addition of androgen receptor signaling inhibitors (ARSIs) alongside standard androgen deprivation therapy (ADT) in advanced prostate cancer was associated with a significantly increased risk of ...

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent cancer and the fifth leading cause of cancer death among men in 2022. Hormone ...

Please provide your email address to receive an email when new articles are posted on . One journal reviewer told Donald P. McDonnell, PhD, the research should be “banned from the literature.” A ...